The Colosseum and Arch of Constantine in Rome. Photo by Konrad Zielinski.

ESC Congress 2016 took place August 27-31 in Rome, Italy.

Longer DAPT better for PAD, study suggests



aspirin_coated_Credit_Sage_Ross_230.jpg
Aspirin tablets
Photo by Sage Ross

A subanalysis of the PRODIGY study suggests a longer duration of dual antiplatelet therapy (DAPT) improves outcomes after percutaneous coronary intervention (PCI) for patients with peripheral arterial disease (PAD). Receiving long-term DAPT after PCI reduced the risk of atherothrombotic events and death in patients with PAD, without increasing... [Read Article]

Simple algorithm can rule out PE, team says



Pulmonary_embolism_CT_scan_of_Credit_Medical_College_of_Georgia_220.jpg
CTPA showing PE
Image courtesy of
Medical College of Georgia

A new study suggests the YEARS algorithm may provide a simple method for ruling out pulmonary embolism (PE) and therefore reduce the need for computed tomography pulmonary angiography (CTPA). “[The YEARS algorithm] can replace current diagnostic algorithms, which, although safe and accurate, are... [Read Article]

Edoxaban appears comparable to standard therapy



warfarin_tablets.jpg
Warfarin tablets

The novel oral anticoagulant edoxaban is a feasible treatment option for patients with atrial fibrillation (AF) who need anticoagulation before cardioversion, according to researchers. Results of the ENSURE-AF trial suggest edoxaban is “an effective and safe alternative” to standard therapy with warfarin and enoxaparin and may allow for prompt cardioversion with transesophageal echocardiography... [Read Article]

Antidote to factor Xa inhibitors exhibits efficacy in patients with major bleeding



rivaroxaban-xarelto-tablets-prweb-240.png
Rivaroxaban tablets

Preliminary results from the ANNEXA-4 study suggest that andexanet alfa, an investigational antidote to factor Xa inhibitors, can be effective in patients with acute major bleeding. The drug reversed the anticoagulant effects of rivaroxaban, apixaban, and enoxaparin in this study, providing “excellent” or “good” hemostatic efficacy in 79% of patients over 12 hours.... [Read Article]

Antiplatelet drugs comparable in patients with AMI



ticagrelor_tablets_Credit_AstraZeneca_230.jpg
Ticagrelor tablets
Photo courtesy of AstraZeneca

The antiplatelet drugs prasugrel and ticagrelor produce similar early results in patients with acute myocardial infarction (AMI) treated with percutaneous coronary intervention (PCI), according to PRAGUE-18, the first randomized, head-to-head comparison of the drugs. “Our findings confirm previous indirect—non-randomized—comparisons of these 2 drugs, based on analyses of various... [Read Article]

Antiplatelet monitoring doesn’t benefit high-risk patient group



doc_and_patient_older_woman_Credit_NIH_230.jpg
Doctor and patient
Photo courtesy of NIH

Results of the ANTARCTIC trial suggest that monitoring platelet function to individualize antiplatelet therapy does not improve outcomes for elderly patients stented for an acute coronary syndrome. These patients had a high risk of ischemic and bleeding complications, but the study showed no significant difference in the... [Read Article]

Rule identifies women at low risk of VTE recurrence



women-three-generations-230.jpg
Three generations
of women in a family

According to researchers, a clinical decision rule can identify women who, after their first unprovoked venous thromboembolism (VTE), have a low risk of VTE recurrence and might safely discontinue anticoagulant therapy. The researchers evaluated the HERDOO2 rule, which is named after the risk factors the rule employs... [Read Article]

Two NOACs pose lower risk of ICH in real-world study



apixaban-eliquis-5mg_Pfizer_BMS_220.jpg
Apixaban tablets
Photo courtesy of Pfizer
and Bristol-Myers Squibb

Novel oral anticoagulants (NOACs) are as effective as warfarin for preventing stroke but may cause less intracranial hemorrhage (ICH) in patients with atrial fibrillation, according to research presented at ESC Congress 2016. For this study, investigators compared 3 NOACs—dabigatran, rivaroxaban, and apixaban—to warfarin in a... [Read Article]

Shorter DAPT appears safe for pts with type of DES



aspirin_bottle_Sage_Ross_230.jpg
Aspirin tablets
Photo by Sage Ross

A short-term course of dual antiplatelet therapy (DAPT) may be non-inferior to a longer course in patients who have a certain type of drug-eluting stent (DES), according to research presented at ESC Congress 2016. Patients in this study, known as NIPPON, had the Nobori bioabsorbable abluminal-coated stent and... [Read Article]